Heart Failure

A discussion on how the economic burden of management differs for patients with HFpEF and HFrEF.

A key opinion leader considers how to ensure patients with HFpEF and HFrEF receive therapy in a timely and appropriate manner.

Recent study findings highlight mixed results following use of this medication among Mississippi and Massachusetts Medicaid beneficiaries.

Our top heart failure articles of the year cover a groundbreaking development for dapagliflozin, address the important issue of disparities in this space, and see coronavirus disease 2019 make yet another appearance.

Expert physicians consider how the treatment of patients differ when they have HFpEF versus HFrEF.

Key opinion leaders enumerate the challenges of treating patients with HFpEF.

Hoping to improve outcomes among patients with acute heart failure discharged from the emergency department, study findings show that 30-day improvements from a self-care intervention were not sustainable through 90 days.

This week, the top managed care news included the first coronavirus disease 2019 vaccine shipments arriving nationwide; FDA panel votes to expand use of heart failure drug; efforts to address social determinants of health amid the pandemic.

A 5-phase program designed to increase knowledge among patients with heart failure has shown promise in more effective disease management and hospital readmission reduction.

The panel could not reach consensus on what an expanded label might look like in an area where there are no approved therapies.

A discussion on utilization management strategies for optimizing the treatment for patients with heart failure.

Key opinion leaders provide an overview of the treatment gaps in the management of heart failure.

Due to a lack of comprehensive data on health literacy among these patients, a team of investigators looked at its connection with their quality of life (QOL).

Top reasons why patients with heart failure face a higher risk of hospitalization during times when fracking occurs include an increase in air pollution and stress pathways.

An expert in the management of heart failure discusses the standard of care for patients with reduced ejection fraction.

Expert physicians consider the treatment goals for patients with heart failure.

Overdose-related cardiac arrests rose consistently in the first few months of the coronavirus disease 2019 (COVID-19) pandemic, coming in at 48.5% above baseline through August 1, according to national emergency medical services data.

A key opinion leader discusses how the medical understanding of heart failure has improved over the years and how it has helped management of disease.

A discussion on the link between LVEF, nT-proBNP, and cardiac remodeling in predicting disease progression.

The 5-year risk of women dying or developing heart failure following a first severe heart attack is 20% higher compared with men, according to the findings in Circulation.

Intravenous (IV) iron reduced rehospitalization risk among patients hospitalized with acute heart failure (HF) and low iron, according to research presented at the American Heart Association’s Scientific Sessions 2020.

An expert in the management of heart failure provides an overview of the progressive nature of the disease, with special consideration to biomarker monitorization.

An in-depth discussion on the clinical and economic burden of treatment for patients with heart failure, with special consideration to progressive disease.

A recent survey of UK Biobank participants showed that healthy sleep habits were associated with a possible lower risk of heart failure among adults, even after adjusting for several confounders.

Dr. Anthony Fauci discusses the cardiovascular implications of coronavirus disease 2019 (COVID-19) at the American Heart Association Scientific Sessions.